Knight Therapeutics Inc. has seen a modest uptick in its stock price this week, driven by a series of positive financial announcements.
Knight Therapeutics Inc. (GUD.TO) reported a slight increase of 0.41% over the past week, closing at C$9.97. The company has recently garnered attention for its strong quarterly results and updated financial guidance, reflecting a positive trajectory in its business operations.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$964.12M
P/E
163.7x
52W high
$10.17
52W low
$5.66
1W change
+0.41%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to fall 0.1% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$9.83
-0.1% Upside
Current Price
C$9.84
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.3%
Annualized
90-Day Vol
30.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.76
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$10.44 | C$9.64 โ C$11.32 |
| 60 trading days | C$11.08 | C$9.89 โ C$12.42 |
| 90 trading days | C$11.76 | C$10.24 โ C$13.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors might find Knight Therapeutics' recent performance encouraging, especially with its improved revenue guidance and repayment of debt, although the high P/E ratio suggests caution.
Knight Therapeutics Reports Record Revenues and Increased Guidance
The company has raised its 2026 revenue guidance from $510 million to $525 million, signaling confidence in its growth trajectory.
Bull case
Knight Therapeutics has reported record-high revenues and adjusted EBITDA, suggesting strong operational performance and promising growth potential.
Bear case
However, with a P/E ratio over 163, some may view the stock as overvalued. Any market corrections could lead to significant volatility, especially given its low beta of 0.05.
Recent Performance
Knight Therapeutics Inc. (GUD.TO) has shown steady performance over the last week, with a modest gain of 0.41%. The stock closed at C$9.97, reflecting a year-to-date increase of 66.50%. This positive trend can be attributed to the company's recent financial announcements and operational successes.
Catalysts Behind the Movement
The recent uptick in Knight Therapeutics' stock is largely due to the company's announcement of record-high quarterly revenues and adjusted EBITDA for Q1 2026. Additionally, the company has raised its revenue guidance for 2026 from $510 million to $525 million, indicating strong growth prospects. Furthermore, the successful repayment of its revolving credit facility has strengthened its financial position.
Technical Picture
Looking at the technical indicators, Knight Therapeutics is trading above its 50-day moving average of C$9.07, representing a 9.9% premium. The stock is also significantly above its 200-day moving average of C$7.01, showing a 42.3% increase. The 52-week range is C$5.66 to C$10.17, indicating that the stock is currently trading at about 96% of its 52-week high. With a beta of 0.05, the stock exhibits low volatility compared to the market.
Insider Activity
As of now, there are no reported insider activities that could influence investor sentiment or stock performance.
Price Action Summary
Knight Therapeutics Inc. closed at C$9.97, reflecting a 1D increase of 0.20%. The stock continues to attract attention as it navigates a positive financial landscape.
Advertisement
